New-onset septic shock in the ImmunoSep trial - Takeaways - MDSpire

New-onset septic shock in the ImmunoSep trial

  • By

  • Ruyuan Zhang

  • April 2, 2026

  • 0 min

Share

  • 1

    The ImmunoSep trial demonstrated that biomarker-guided immunotherapy improved organ dysfunction in sepsis patients compared to placebo.

  • 2

    Septic shock occurred in 22.1% of patients receiving immunotherapy versus 11.7% in the placebo group, indicating a potential increased risk.

  • 3

    The observed differences in septic shock incidence should be interpreted cautiously due to small event counts and statistical fragility.

  • 4

    Mechanistically, the increased septic shock incidence may result from immune dysregulation or treatment-related changes in host response.

  • 5

    Safety analyses in randomized trials are descriptive, and new-onset septic shock may reflect disease trajectory rather than drug toxicity.

Original Source(s)

New-onset septic shock in the ImmunoSep trial

  • by Ruyuan Zhang

  • April 2, 2026

Related Content

Assessing the Prognostic Significance of Interleukin-6, Neuropilin-1, and Amphiregulin Levels for Mortality Prediction in ICU Patients with Sepsis or Septic Shock

Xiangdan Injection Mitigates Cardiac Injury in Experimental Sepsis through Inflammatory Suppression and Mitochondrial Protection

Exploring GSTP1 as a Potential Protective Target in Sepsis: Insights from Proteome-Wide Mendelian Randomization and Multi-Omics Studies